Q32 Bio Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $8.63
- 52-Week Range
- $1.91 – $23.57
- Market Cap
- $255.25M
- P/E (TTM)
- 2.37
- EPS (TTM)
- 3.60
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.89
- PEG Ratio
- —
- Return on Equity
- 23.96%
- Return on Assets
- 6.47%
- Gross Margin
- 70.34%
- Operating Margin
- 34.20%
- Profit Margin
- 60.02%
- Current Ratio
- 56.34
- Debt/Equity
- 0.02
- Total Debt
- $5.12M
- Free Cash Flow
- $19.48M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $-29.21M
Market Snapshot
About
Q32 Bio is a clinical-stage biotechnology company developing therapies targeting the complement pathway for immune-mediated diseases. The company focuses on conditions like atopic dermatitis, asthma, and inflammatory bowel disease. Q32 Bio uses a precision approach to modulate specific complement components, aiming for targeted efficacy with reduced side effects compared to broader immunosuppression.